{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:23:56Z","timestamp":1792650236656,"version":"4.5.0"},"reference-count":155,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The tumor microenvironment (TME) is a unique landscape that poses several physical, biochemical, and immune barriers to anti-cancer therapies. The rapidly evolving field of immuno-engineering provides new opportunities to dismantle the tumor immune microenvironment by efficient tumor destruction. Systemic delivery of such treatments can often have limited local effects, leading to unwanted offsite effects such as systemic toxicity and tumor resistance. Interventional radiologists use contemporary image-guided techniques to locally deliver these therapies to modulate the immunosuppressive TME, further accelerating tumor death and invoking a better anti-tumor response. These involve local therapies such as intratumoral drug delivery, nanorobots, nanoparticles, and implantable microdevices. Physical therapies such as photodynamic therapy, electroporation, hyperthermia, hypothermia, ultrasound therapy, histotripsy, and radiotherapy are also available for local tumor destruction. While the interventional radiologist can only locally manipulate the TME, there are systemic offsite recruitments of the immune response. This is known as the abscopal effect, which leads to more significant anti-tumoral downstream effects. Local delivery of modern immunoengineering methods such as locoregional CAR-T therapy combined with immune checkpoint inhibitors efficaciously modulates the immunosuppressive TME. This review highlights the various advances and technologies available now to change the TME and revolutionize oncology from a minimally invasive viewpoint.<\/jats:p>","DOI":"10.3390\/cancers15010196","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:52:21Z","timestamp":1672282341000},"page":"196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-2260","authenticated-orcid":false,"given":"Koustav","family":"Pal","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-8985","authenticated-orcid":false,"given":"Rahul A.","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: Back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole Body Irradiation\u2014Radiobiology or Medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br. J. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Allen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PPO.0000000000000136","article-title":"Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years\u2019 Journey HHS Public Acces","volume":"21","author":"Jain","year":"2015","journal-title":"Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S1470-2045(07)70140-7","article-title":"Active versus passive mechanisms in metastasis: Do cancer cells crawl into vessels, or are they pushed?","volume":"8","author":"Bockhorn","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100845","DOI":"10.1016\/j.tranon.2020.100845","article-title":"Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis","volume":"13","author":"Saxena","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4161\/cam.4.3.11790","article-title":"Hypoxia response pathway in border cell migration","volume":"4","author":"Djagaeva","year":"2010","journal-title":"Cell Adhes. Migr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1074\/jbc.M112.442939","article-title":"Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts","volume":"288","author":"Gilkes","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/sj.bjc.6605450","article-title":"Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene","volume":"102","author":"Buffa","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: A novel approach to developing treatment","volume":"21","author":"Nejad","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"Rohwer","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2009","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ijc.21422","article-title":"Macrophage migration and gene expression in response to tumor hypoxia","volume":"117","author":"Murdoch","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","article-title":"Targeting hypoxia in the tumor microenvironment: A potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Feng, J., Byrne, N.M., Al Jamal, W., and Coulter, J.A. (2019). Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development. Cancers, 11.","DOI":"10.3390\/cancers11121989"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"a027094","DOI":"10.1101\/cshperspect.a027094","article-title":"Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity","volume":"6","author":"Martin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/1319-3767.37808","article-title":"Sorafenib in the treatment of advanced hepatocellular carcinoma","volume":"14","year":"2008","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2019","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc.2017.77","article-title":"Tumour acidosis: From the passenger to the driver\u2019s seat","volume":"17","author":"Corbet","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1038\/s41598-020-70396-1","article-title":"The control of acidity in tumor cells: A biophysical model","volume":"10","author":"Piasentin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/ijc.30646","article-title":"Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-\u03b3 and induces NK cell-dependent lymphoma control without other immunotherapies","volume":"140","author":"Roser","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-016-0004","article-title":"Solid stress and elastic energy as measures of tumour mechanopathology","volume":"1","author":"Nia","year":"2016","journal-title":"Nat. Biomed. Eng."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches","volume":"9","author":"Nacional","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1748-717X-4-47","article-title":"AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK\/JNK pathway and enhances radiation-induced apoptosis","volume":"4","author":"Zerp","year":"2009","journal-title":"Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses","volume":"11","author":"Loskog","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1038\/s41467-021-23946-8","article-title":"Tumor microenvironmental cytokines bound to cancer exosomes determine uptake by cytokine receptor-expressing cells and biodistribution","volume":"12","author":"Lima","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1615\/CritRevOncog.2015013668","article-title":"Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment","volume":"20","author":"Murgai","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"ref_37","first-page":"55","article-title":"Targeting tumor microenvironment: Crossing tumor interstitial fluid by multifunctional nanomedicines","volume":"4","author":"Omidi","year":"2014","journal-title":"BioImpacts"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fbioe.2021.625859","article-title":"The Cancer Microenvironment: Mechanical Challenges of the Metastatic Cascade","volume":"9","author":"Amos","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e001800","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Williams","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-chembioeng-061010-114300","article-title":"Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies","volume":"2","author":"Chauhan","year":"2011","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","first-page":"3195","article-title":"Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e207911","DOI":"10.1001\/jamanetworkopen.2020.7911","article-title":"Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer","volume":"3","author":"Sheth","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23838","DOI":"10.1039\/D0NR05053A","article-title":"Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma","volume":"12","author":"Brachi","year":"2020","journal-title":"Nanoscale"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1628","article-title":"Disrupting tumour blood vessels","volume":"5","author":"Tozer","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317691001","article-title":"Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation","volume":"39","author":"Seidi","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.drudis.2020.03.005","article-title":"DNA-nanorobot-guided thrombin-inducing tumor infarction: Raising new potential clinical concerns","volume":"25","author":"Zheng","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nbt.4071","article-title":"A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo","volume":"36","author":"Li","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41598-020-61586-y","article-title":"Self-Propelling Targeted Magneto-Nanobots for Deep Tumor Penetration and pH-Responsive Intracellular Drug Delivery","volume":"10","author":"Andhari","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/acs.accounts.9b00283","article-title":"Smart Nanotherapeutic Targeting of Tumor Vasculature","volume":"52","author":"Li","year":"2019","journal-title":"Accounts Chem. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for Cancer Therapy: Current Progress and Challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbamem.2009.06.022","article-title":"Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer","volume":"1788","author":"Li","year":"2009","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Biomembr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: Principles, Properties, and Regulatory Issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front. Chem."},{"key":"ref_56","first-page":"129","article-title":"Nanoparticles in modern medicine: State of the art and future challenges","volume":"2","author":"Murthy","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4143\/crt.2016.376","article-title":"An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.2147\/IJN.S198552","article-title":"Development of anti-HER2-targeted doxorubicin\u2013core-shell chitosan nanoparticles for the treatment of human breast cancer","volume":"14","author":"Naruphontjirakul","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/biot.201100054","article-title":"Current progress of siRNA\/shRNA therapeutics in clinical trials","volume":"6","author":"Burnett","year":"2011","journal-title":"Biotechnol. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fbioe.2018.00170","article-title":"Frontiers of Medical Micro\/Nanorobotics: In vivo Applications and Commercialization Perspectives Toward Clinical Uses","volume":"6","author":"Soto","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jmmm.2018.08.048","article-title":"Magnetic drilling enhances intra-nasal transport of particles into rodent brain","volume":"469","author":"Jafari","year":"2018","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.addr.2018.09.005","article-title":"Micromotors for drug delivery in vivo: The road ahead","volume":"138","author":"Srivastava","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11051-008-9446-4","article-title":"Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies","volume":"11","author":"Jiang","year":"2008","journal-title":"J. Nanoparticle Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.pmatsci.2011.08.003","article-title":"Zero-dimensional, one-dimensional, two-dimensional and three-dimensional nanostructured materials for advanced electrochemical energy devices","volume":"57","author":"Tiwari","year":"2012","journal-title":"Prog. Mater. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1002\/wnan.1571","article-title":"Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting","volume":"11","author":"Liu","year":"2019","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737159.6.3.307","article-title":"Nanotechnology for cancer diagnostics: Promises and challenges","volume":"6","author":"Grodzinski","year":"2006","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/nnm.12.87","article-title":"Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system","volume":"7","author":"Bamrungsap","year":"2012","journal-title":"Nanomedicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/21691401.2017.1375937","article-title":"Nanomaterials as nanocarriers: A critical assessment why these are multi-chore vanquisher in breast cancer treatment","volume":"46","author":"Naz","year":"2017","journal-title":"Artif. Cells, Nanomedicine, Biotechnol."},{"key":"ref_70","unstructured":"(2022, August 03). Implantable and Microparticle Depot Systems Meet Needs of Drug Delivery. Available online: https:\/\/www.europeanpharmaceuticalreview.com\/article\/122140\/how-implantable-systems-and-microparticle-depot-injections-are-meeting-the-needs-of-long-acting-drug-delivery\/."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jnt3010003","article-title":"Implantable Devices for the Treatment of Breast Cancer","volume":"3","author":"Pial","year":"2022","journal-title":"J. Nanotheranostics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1109\/TBME.2021.3096126","article-title":"The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients","volume":"69","author":"Dominas","year":"2021","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1021\/jacs.6b01784","article-title":"An Implantable Depot That Can Generate Oxygen in Situ for Overcoming Hypoxia-Induced Resistance to Anticancer Drugs in Chemotherapy","volume":"138","author":"Huang","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1080\/10717544.2022.2075984","article-title":"Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment","volume":"29","author":"Kong","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biomaterials.2018.05.005","article-title":"Replenishable drug depot to combat post-resection cancer recurrence","volume":"178","author":"Brudno","year":"2018","journal-title":"Biomaterials"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"284ra57","DOI":"10.1126\/scitranslmed.3010564","article-title":"An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors","volume":"7","author":"Jonas","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41587-022-01379-y","article-title":"A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs","volume":"40","author":"Tatarova","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1515\/bmc-2022-0010","article-title":"Targeted Photoimmunotherapy for Cancer","volume":"13","author":"Mussini","year":"2022","journal-title":"Biomol Concepts"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.breast.2016.09.016","article-title":"Photodynamic therapy: Inception to application in breast cancer","volume":"31","author":"Banerjee","year":"2016","journal-title":"Breast"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s43046-021-00093-1","article-title":"Implications of photodynamic cancer therapy: An overview of PDT mechanisms basically and practically","volume":"33","author":"Sobhani","year":"2021","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1533034614556192","article-title":"Photodynamic Therapy and Its Role in Combined Modality Anticancer Treatment","volume":"14","author":"Brodin","year":"2014","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3389\/fimmu.2018.02909","article-title":"Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend","volume":"9","author":"Locy","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/156800961601151218155340","article-title":"Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols","volume":"16","author":"Spugnini","year":"2015","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bonferoni, M.C., Rassu, G., Gavini, E., Sorrenti, M., Catenacci, L., Torre, M.L., Perteghella, S., Ansaloni, L., Maestri, M., and Giunchedi, P. (2021). Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible \u201cEPR Effect Enhancer\u201d to Improve Cancer Nanomedicine Efficacy. Cancers, 13.","DOI":"10.3390\/cancers13174437"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.2020192190","article-title":"High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy","volume":"295","author":"Geboers","year":"2020","journal-title":"Radiology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1464-410X.2008.07793.x","article-title":"Antitumour effect of electrochemotherapy with bleomycin on human prostate cancer xenograft","volume":"102","author":"Ueki","year":"2008","journal-title":"Br. J. Urol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.3389\/fonc.2021.772144","article-title":"The Role of Electrochemotherapy in the Cutaneous and Subcutaneous Metastases From Breast Cancer: Analysis of Predictive Factors to Treatment From an Italian Cohort of Patients","volume":"11","author":"Russano","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1038\/s41598-020-67772-2","article-title":"Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma","volume":"10","author":"Hsiao","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Guenther, E., Klein, N., Zapf, S., Weil, S., Schlosser, C., Rubinsky, B., and Stehling, M.K. (2019). Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215093"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3389\/fonc.2020.575992","article-title":"Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment","volume":"10","author":"Carrieri","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"103535","DOI":"10.1016\/j.critrevonc.2021.103535","article-title":"Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates","volume":"168","author":"Arvind","year":"2021","journal-title":"Crit. Rev. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: Current advances and future directions","volume":"124","author":"Rominiyi","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Adnan, A., Mu\u00f1oz, N., Prakash, P., Habibollahi, P., Cressman, E., and Sheth, R. (2021). Hyperthermia and Tumor Immunity. Cancers, 13.","DOI":"10.3390\/cancers13112507"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s42003-020-01522-y","article-title":"Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma","volume":"3","author":"Dupuis","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Jiang, A.-N., Wang, B., Wang, S., Zhao, K., Wu, H., Yan, K., Wu, W., and Yang, W. (2022). The study of direct and indirect effects of radiofrequency ablation on tumor microenvironment in liver tumor animal model. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09730-x"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1148\/radiol.15141215","article-title":"Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance","volume":"276","author":"Kang","year":"2015","journal-title":"Radiology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1148\/radiol.2017162943","article-title":"Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation","volume":"286","author":"Kumar","year":"2018","journal-title":"Radiology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1148\/radiol.2015150080","article-title":"Hepatic Radiofrequency Ablation\u2013induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition","volume":"279","author":"Ahmed","year":"2016","journal-title":"Radiology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.3748\/wjg.v24.i33.3695","article-title":"Updates on the hepatocyte growth factor\/c-Met axis in hepatocellular carcinoma and its therapeutic implications","volume":"24","author":"Medina","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1067\/j.cpradiol.2007.10.001","article-title":"Radiofrequency and Microwave Ablation of the Liver, Lung, Kidney, and Bone: What Are the Differences?","volume":"38","author":"Brace","year":"2009","journal-title":"Curr. Probl. Diagn. Radiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","article-title":"Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma","volume":"70","author":"Leuchte","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"696749","DOI":"10.3389\/fimmu.2021.696749","article-title":"Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e002343","DOI":"10.1136\/jitc-2021-002343","article-title":"Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer","volume":"9","author":"Zhou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/j.jvir.2009.04.011","article-title":"Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria","volume":"20","author":"Goldberg","year":"2009","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/02656736.2019.1647355","article-title":"Cryoablation: Physical and molecular basis with putative immunological consequences","volume":"36","author":"Baust","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ijc.1359","article-title":"Induction of apoptosis in human colon carcinoma cells HT29 by sublethal cryo-injury: Mediation by cytochrome c release","volume":"93","author":"Hanai","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1464-410X.2005.05502.x","article-title":"The molecular basis of cryosurgery","volume":"95","author":"Baust","year":"2005","journal-title":"BJU Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.jvir.2009.12.403","article-title":"Cryoablation: Mechanism of Action and Devices","volume":"21","author":"Erinjeri","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"930461","DOI":"10.3389\/fimmu.2022.930461","article-title":"Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"18229","DOI":"10.1038\/s41598-022-22279-w","article-title":"Comparative analysis of the immune response to RFA and cryoablation in a colon cancer mouse model","volume":"12","author":"Hawken","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_113","first-page":"531","article-title":"Ultrasounds in cancer therapy: A summary of their use and unexplored potential","volume":"16","author":"Gomez","year":"2022","journal-title":"Oncol. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ultrasmedbio.2012.09.004","article-title":"Probability of Cavitation for Single Ultrasound Pulses Applied to Tissues and Tissue-Mimicking Materials","volume":"39","author":"Maxwell","year":"2013","journal-title":"Ultrasound Med. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ultras.2009.06.002","article-title":"Potential mechanism in sonodynamic therapy and focused ultrasound induced apoptosis in sarcoma 180 cells in vitro","volume":"49","author":"Tang","year":"2009","journal-title":"Ultrasonics"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e003717","DOI":"10.1136\/jitc-2021-003717","article-title":"Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity","volume":"10","author":"Abe","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41598-020-80135-1","article-title":"Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer","volume":"11","author":"Fite","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","article-title":"Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development Study","volume":"68","author":"Ahmed","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e22610","DOI":"10.1097\/MD.0000000000022610","article-title":"The primary treatment of prostate cancer with high-intensity focused ultrasound","volume":"99","author":"He","year":"2020","journal-title":"Medicine"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ultrasmedbio.2007.07.013","article-title":"Changes in Circulating Immunosuppressive Cytokine Levels of Cancer Patients after High Intensity Focused Ultrasound Treatment","volume":"34","author":"Zhou","year":"2008","journal-title":"Ultrasound Med. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/02656736.2021.1905189","article-title":"Histotripsy: The first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound","volume":"38","author":"Xu","year":"2021","journal-title":"Int. J. Hyperth."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"681629","DOI":"10.3389\/fonc.2021.681629","article-title":"Immunological Effects of Histotripsy for Cancer Therapy","volume":"11","author":"Hutchison","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MOU.0000000000000001","article-title":"Development and translation of histotripsy: Current Status and Future Directions","volume":"24","author":"Roberts","year":"2014","journal-title":"Curr. Opin. Urol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"225001","DOI":"10.1088\/1361-6560\/ab5010","article-title":"Modeling tissue-selective cavitation damage","volume":"64","author":"Mancia","year":"2019","journal-title":"Phys. Med. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jvir.2019.01.023","article-title":"Robotically-Assisted Sonic Therapy for Renal Ablation in a Live Porcine Model: Initial Preclinical Results","volume":"30","author":"Knott","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ultrasmedbio.2017.01.016","article-title":"Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model","volume":"43","author":"Vlaisavljevich","year":"2017","journal-title":"Ultrasound Med. Biol."},{"key":"ref_127","unstructured":"(2022, August 03). Study to Evaluate VORTX Rx (Theresa)\u2014Full Text View\u2014ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03741088."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/02656736.2022.2112309","article-title":"First-in-man histotripsy of hepatic tumors: The THERESA trial, a feasibility study","volume":"39","author":"Serres","year":"2022","journal-title":"Int. J. Hyperth."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2016.10.007","article-title":"A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer","volume":"243","author":"Dimcevski","year":"2016","journal-title":"J. Control Release"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0031-1274749","article-title":"Invited Editorial\u2014Sonoporation: Why Microbubbles Create Pores","volume":"33","author":"Postema","year":"2012","journal-title":"Ultraschall Med.\u2014Eur. J. Ultrasound"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.semcancer.2022.02.011","article-title":"Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells","volume":"86","author":"Berg","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13014-020-01678-1","article-title":"Reprogramming the tumour microenvironment by radiotherapy: Implications for radiotherapy and immunotherapy combinations","volume":"15","author":"Colton","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41591-020-01190-9","article-title":"Liver metastases inhibit immunotherapy efficacy","volume":"27","author":"Lindblad","year":"2021","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"106663","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13014-019-1423-9","article-title":"Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment","volume":"14","author":"Tubin","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"612072","DOI":"10.3389\/fimmu.2020.612072","article-title":"Advances in Hypofractionated Irradiation-Induced Immunosuppression of Tumor Microenvironment","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Haviland","year":"2020","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1148\/radiol.220158","article-title":"Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET\/CT in Women with Breast Cancer Liver Metastasis","volume":"306","author":"Deipolyi","year":"2023","journal-title":"Radiology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","article-title":"Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma","volume":"33","author":"Kallini","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jvir.2022.08.031","article-title":"Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review","volume":"33","author":"Alexander","year":"2022","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: A first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.omto.2021.12.018","article-title":"Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors","volume":"24","author":"Kimura","year":"2021","journal-title":"Mol. Ther.\u2014Oncolytics"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s12094-022-02830-x","article-title":"Oncolytic viral vectors in the era of diversified cancer therapy: From preclinical to clinical","volume":"24","author":"Tang","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/cco.2018.04.04","article-title":"The emerging role of oncolytic virus therapy against cancer","volume":"7","author":"Russell","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/2020.11.FOCUS20845","article-title":"Intraarterial delivery of virotherapy for glioblastoma","volume":"50","author":"Srinivasan","year":"2021","journal-title":"Neurosurg. Focus"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/cgt.2009.19","article-title":"Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors","volume":"16","author":"Xu","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1073\/pnas.1904022116","article-title":"Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer","volume":"117","author":"Newman","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e10375","DOI":"10.15252\/emmm.201910375","article-title":"Repurposing the yellow fever vaccine for intratumoral immunotherapy","volume":"12","author":"Aznar","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2015","journal-title":"Lancet"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:47Z","timestamp":1760147687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":155,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010196"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010196","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}